RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Junshi Biosciences rose 22% in its first trading session on the Hong Kong Exchange following its $394 million IPO. Last week, Junshi announced its lead drug candidate, Tuoyi (toripalimab), an anti-PD-1 molecule, was approved by China’s NMPA as a second-line treatment for melanoma. It is the first domestic PD-1 approved in China. Junshi has 13 products in development, five of them clinical stage. The IPO was completed at a nearly $2 billion valuation, and the company now has a market capitalization of $2.4 billion.
Source: China Biotoday
